CCR5 deficiency does not prevent P0 peptide 180–199 immunized mice from experimental autoimmune neuritis

• Main Authors: Rui-Sheng Duan, Zhiguo Chen, Lei Bao, Hernan Concha Quezada, Inger Nennesmo, Bengt Winblad, Jie Zhu
• Format: Article
• Language: English
• Published: Elsevier 2004-08-01
• Series: Neurobiology of Disease
• Subjects: CCR5; Experimental autoimmune neuritis; Guillain–Barré syndrome; IP-10; MIP-1β
• Online Access: http://www.sciencedirect.com/science/article/pii/S096999610400097X

Experimental autoimmune neuritis (EAN) is an inflammatory autoimmune demyelinating disease of peripheral nervous system (PNS) and represents an animal model of Guillain–Barré syndrome (GBS) in man. The inflammatory cell infiltrating into the PNS is a prerequisite for developing EAN. To explore the role of CC chemokine receptor 5 (CCR5) in the inflammatory process of EAN, we induced EAN in CCR5-deficient (CCR5−/−) mice with P0 protein peptide 180–199. We found that CCR5−/− mice showed a similar EAN clinical course and severity as well as profile of infiltrating macrophages and T cells in cauda equina (CE) of EAN and the same levels of spleen mononuclear cell (MNC) response to antigen and mitogen when compared with CCR5+/+ control mice. However, increased IP-10 and MIP-1β production in sciatic nerves were seen in CCR5−/− mice. These results suggest that CCR5 deficiency does not prevent P0 peptide 180–199-immunized mice from EAN. Increased MIP-1β and IP-10 in sciatic nerves may compensate the CCR5 deficiency and contribute to inflammatory cells infiltrating to the PNS.